Table 2

 Changes from baseline in patient-reported outcomes in Adalimumab Effectiveness in Psoriatic Arthritis Trial*

Patient-reported outcomeWeek 12Week 24
PlaceboAdalimumabp Value†PlaceboAdalimumabp Value†
DLQI, Dermatology Life Quality Index; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy—Fatigue Scale; HAQ DI, Health Assessment Questionnaire Disability Index; MCS, mental component summary; PCS, physical component summary; SF-36, Short Form 36 Health Survey; VAS, visual analogue scale.
*Values are mean (SD) (n) change from baseline, by the last observation carried forward analysis.
†For differences between treatment groups from an analysis of variance model with treatment group, and baseline methotrexate use (yes/no) and extent of psoriasis (⩾3%, <3% body surface area) as factors.
‡Patient’s assessment of pain is based on VAS possible range of 0 (no pain) to 100 (pain as bad as it could be).
§Patient’s global assessment of disease activity is based on VAS possible range of 0 (very well) to 100 (very poorly).
HAQ DI−0.1 (0.5) (162)−0.4 (0.5) (151)<0.001−0.1 (0.4) (162)−0.4 (0.5) (151)<0.001
SF-36 PCS1.4 (8.7) (151)9.3 (10.0) (136)<0.0011.4 (9.6) (152)9.3 (10.1) (140)<0.001
SF-36 MCS1.2 (10.2) (151)1.6 (10.1) (136)0.7080.6 (10.4) (152)1.8 (9.3) (140)0.288
Physical functioning3.9 (23.3) (151)14.4 (22.1) (139)<0.0012.9 (23.8) (152)15.8 (22.9) (143)<0.001
Role-physical7.2 (34.8) (152)30.1 (41.9) (138)<0.0018.9 (43.4) (152)30.0 (38.5) (142)<0.001
Bodily pain3.0 (20.5) (152)19.6 (23.4) (141)<0.0013.4 (18.9) (152)21.8 (22.8) (143)<0.001
General health0.2 (16.7) (152)12.4 (18.2) (139)<0.001−0.1 (16.8) (152)11.6 (19.4) (143)<0.001
Vitality3.0 (17.2) (152)13.7 (20.4) (138)<0.0011.7 (19.1) (152)12.8 (21.0) (141)<0.001
Social functioning4.4 (23.4) (152)11.8 (25.7) (140)0.0142.6 (25.4) (152)11.8 (25.8) (143)0.003
Role-emotional4.4 (46.8) (152)5.7 (45.3) (138)0.7624.6 (48.5) (152)10.3 (40.3) (142)0.255
Mental health1.8 (15.0) (152)5.1 (14.9) (138)0.0601.1 (14.9) (152)4.5 (15.3) (141)0.045
FACIT-Fatigue0.6 (8.4) (148)6.5 (11.1) (140)<0.0010.1 (9.6) (151)7.1 (10.2) (143)<0.001
Patient’s assessment of pain‡1.6 (24.0) (161)−23.0 (27.0) (151)<0.0010.6 (24.1) (161)−24.0 (28.3) (151)<0.001
Patient’s global assessment of disease activity§0.4 (23.1) (161)−19.6 (29.4) (151)<0.0010.6 (24.5) (161)−21.1 (29.4) (151)<0.001
DLQI−0.4 (5.8) (64)−5.6 (5.6) (66)<0.001−0.7 (6.7) (66)−6.1 (6.3) (66)<0.001